MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Real World Clinical Outcomes Using a Novel Directional Lead from a Multicenter Registry of DBS for Parkinson’s disease

    G. Deuschl, R. Jain, H. Scholtes, K. Steinke, A. Wang, M. Pötter-Nerger, L. Timmermann, J. Volkmann, A. Kühn, P. Eldridge, J. Fitzgerald, H. Mehdorn, J. Vesper (Kiel, Germany)

    Objective: To evaluate clinical outcomes in subjects implanted with a Directional Lead for use in the treatment of levodopa-responsive Parkinson’s disease (PD) as part of…
  • 2017 International Congress

    Levodopa effect and motor function in late stage Parkinson’s disease

    K. Rosqvist, P. Odin, M. Horne, P. Hagell, S. Iwarsson, M. Nilsson (Lund, Sweden)

    Objective: To assess responsiveness to Levodopa (L-dopa) in patients with late stage Parkinson’s disease (PD). Moreover, to investigate if the L-dopa effect is stable or…
  • 2017 International Congress

    Baseline characteristics of the population enrolled to a randomized clinical study of subcutaneous levodopa/carbidopa (ND0612) infusion in patients with advanced PD

    W. Olanow, A. Ellenbogen, R. Djaldetti, T. Rachmilewitz Minei, Y. Cohen, S. Oren, K. Kieburtz (New York, NY, USA)

    Objective: To evaluate whether continuous 24 hours delivery of subcutaneous ND0612 offers practical and clinical benefits over continuous delivery over the waking day (14 hours).…
  • 2017 International Congress

    Identification of the optimal carbidopa concentration in subcutaneously administered ND0612

    L. Adar, T. Rachmilewitz Minei, S. Oren (Rehovot, Israel)

    Objective: To identify the concentration of subcutaneous (SC) carbidopa (CD) that provides optimal bioavailability of a concomitant fixed concentration of levodopa (LD) when administered via…
  • 2017 International Congress

    A long-term study on effectiveness of levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease patients

    K.R. Chaudhuri, A. Antonini, W. Poewe, D. Standaert, P. Odin, J. Zamudio, L. Bergmann (London, United Kingdom)

    Objective: To present the design of and baseline patient characteristics from an ongoing global study assessing the long-term effectiveness of levodopa-carbidopa intestinal gel (LCIG, carbidopa-levodopa…
  • 2017 International Congress

    Physical activity habits in early Parkinson’s disease and healthy controls

    A. Amara, N. Seedorff, L. Chahine, K. Kieburtz, C. Caspell-Garcia, T. Simuni (Birmingham, AL, USA)

    Objective: Investigate the physical activity habits of Parkinson’s disease (PD) and healthy control (HC) participants of the PPMI cohort.  Background: Exercise can improve the motor…
  • 2017 International Congress

    Effect of deep brain stimulation on visuospatial impairment in Parkinson’s disease

    Y. Okahara, Y. Higuchi, K. Aoyagi, M. Abe, T. Yamamoto, Y. Yamanaka, S. Hirano, Y. Iwadate (Chiba, Japan)

    Objective: We evaluated postoperative change of visuospatial impairment in the patients with Parkinson’s disease (PD) underwent deep brain stimulation (DBS) to assess the impact of…
  • 2017 International Congress

    Functional Connectivity Differences Across Parkinson Disease Subtypes

    M. Campbell, C. Gratton, J. Koller, W. Shannon, C. Lessov-Schlaggar, S. Petersen, J. Perlmutter (St. Louis, MO, USA)

    Objective: The goals of this project were to 1) identify putative Parkinson disease (PD) clinical subtypes and 2) investigate resting-state functional connectivity differences between these…
  • 2017 International Congress

    A follow-up study of hyperechogenicity of the substantia nigra in Parkinson’s disease and atypical parkinsonian syndrome

    J. Horie, H. Fujita, K. Suzuki, A. Numao, Y. Watanabe, T. Matsubara, T. Uchiyama, T. Miyamoto, M. Miyamoto, T. Kadowaki, K. Hirata (Shimotsuga-gun, Japan)

    Objective: To evaluate whether the hyperechogenic size of the substantia nigra changes with time in Parkinson's disease (PD) and atypical parkinsonian syndromes (APSs), such as…
  • 2017 International Congress

    Swallowing difficulties and Parkinson’s disease

    S. Polychronis, G. Dervenoulas, G. Pagano, F. Niccolini, M. Politis (London, United Kingdom)

    Objective: To investigate whether swallowing difficulties are associated with presynaptic dopaminergic deficits, distinct clinical phenotypes, CSF biomarkers as well as whether they can predict motor…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley